Redefining how the world approaches, prevents, and heals mental health disorders.
We are a clinical-stage biopharmaceutical company accelerating the development of highly effective mental health treatments that address the unmet needs of patients.
LEARN MORE
For everyone, everywhere
OUR PERSPECTIVE
Shortcomings of existing therapies
Current standard of care treatments are ineffective for millions worldwide.
Significant burden
Affected People
Global population with mental health disorders
Of US population impacted
Expected that more than half of US population will have a mental health disorder at some point in their lifetime
Global economic impact
Estimated global economic costs of mental health disorders by 2030
Recent impact of COVID-19
Percentage of US adults experiencing symptoms of depression and anxiety rose from 11% in 2019 to 42% end of 2020
Urgent need for innovation
Respond inadequately
A third of patients with depression respond inadequately or relapse with current treatments within certain indications
Slow onset of treatment effect
Frontline treatments for depression and anxiety have slow onset (4-12w)
Relapse rate
Most of the patients treated for opioid use disorder (OUD) relapse
Psychiatry approvals since 2015
Only 17 new drugs approved by the FDA for psychiatry disorders since 2015 – less than 20% relative to oncology (N=107)
Our unique approach
Compounds with prior evidence in humans
To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.
Enabling platform technologies
Accelerated drug development
By pooling resources and best practices, we aim to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.
Learn more about our approach
OUR PROGRAMSNews & Insights
News
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company…
News
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent,…
News
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company…